Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2023   |   Volume: 12   |   Issue: 6   |   Page: 1-5     View issue

Review of the Literature and Current State of Knowledge on the Management of Lung Neuroendocrine Neoplasms

 

Krzysztof Jurkiewicz1, Michał Miciak1*, Krzysztof Kaliszewski1

1Department of General, Minimally Invasive and Endocrine Surgery, Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland.


Abstract

Lung neuroendocrine neoplasms (LNENs) are lesions originating from diffuse endocrine cells within the bronchial walls and lung parenchyma. In recent years, there have been significant advances in the diagnosis and therapy of these neoplasms. This paper reviews recent developments in these areas, focusing on the latest research and treatment strategies. In the context of diagnosis, new imaging technologies including high-resolution computed tomography (CT), high-resolution and positron emission tomography-computed tomography (PET-CT) imaging, are providing more precise information on tumor spread and evaluation of metabolic activity. Advances in the field of molecular biomarkers allow a more personalized approach to the diagnosis of LNENs. In the therapeutic area, new targeted drugs and immunotherapy are showing promise in the treatment of LNENs. The development of molecular therapies such as tyrosine kinase inhibitors and somatostatin analogs, is opening up new treatment perspectives, increasing the efficacy of therapy, and improving patient quality of life. The paper also focuses on important research directions and clinical advances in the diagnosis and therapy of LNENs, presenting the current state of knowledge about these rare tumors. The conclusions aim to provide a synthetic view of the latest developments in the field, encouraging further research and improving treatment strategies for LNENs.

Keywords: Lung neuroendocrine neoplasms, Neuroendocrine neoplasms, Molecular biomarkers, Imaging techniques, Targeted therapy, Immunotherapy


Introduction

Lung neuroendocrine neoplasms (LNENs) currently represent about 30% of all neuroendocrine tumors detected and 1-2% of all lung neoplasms.[1, 2] We classify them histologically into four main groups: typical carcinomas (TCs), atypical carcinomas (ACs), large cell neuroendocrine carcinomas (LCNENs), and small cell carcinomas (SCCs).[3, 4] In terms of the differentiation of cells in the tumor, TCs and ACs are well-differentiated tumors.[5, 6] TCs are tumors with low malignancy and long survival, while ACs are tumors with intermediate malignancy and varying clinical behavior.[7, 8] The other 2 groups, LCNECs, and SCCs – are poorly differentiated high-grade tumors with short survival times. These lesions are graded according to mitotic activity, presence of necrosis, and Ki-67 proliferation index.[9, 10] Patients with LNENs present symptoms such as cough, hemoptysis, dyspnea, and chest pain.[11, 12] There is a necessity to closely compare these symptoms with those of typical lung cancers, which can significantly affect the quickness and accuracy of diagnosis.[13, 14] Importantly, LNENs can produce and secrete a variety of substances, such as hormones or neuropeptides which can lead to a variety of clinical manifestations and influence therapeutic strategies.[4, 15] It is also important to note the dependence of symptom severity with increasing tumor stage. The survival rate of patients with LNENs depends on many factors, including tumor type, stage of the disease (Table 1), and effectiveness of the provided treatment. Contemporary advances in diagnostics, including modern imaging technologies and the identification of molecular biomarkers improve the detectability and efficacy of therapy. However, there is still a need for research into new treatment strategies and a better understanding of the biology of these rare neoplasms to enhance the prognosis and patient quality of life.[3]

 

 

 

 

 

 

Table 1. Stage of disease resulting from TNM classification

Stage

Description

0

tumor in situ (Tis)

IA

tumor limited to the lung, size ≤2 cm, without lymph node metastases or distant metastases

IB

tumor limited to the lung, size >2 cm to ≤5 cm, without lymph node metastases or distant metastases

IIA

tumor limited to the lung, size >5 cm, without lymph node metastases or distant metastases

IIB

tumor limited to the lung, size >5 cm, with lymph node metastases, without distant metastases

IIIA

tumor of any size, with lymph node metastases on the same side, without distant metastases

IIIB

tumor of any size with metastases to lymph nodes on the contralateral side or the mediastinal space, as well as a tumor of any size with metastases to lymph nodes on the same side but with metastases to lymph nodes on the contralateral side

IV

tumor with distant metastases, such as metastases to lymph nodes external to the thoracic area or metastases to distant organs

 

Materials and Methods

The review was performed based on PubMed, PubMed Central, and Google Scholar online databases. Papers concerning the last 10 years of LNEN's management were taken into consideration. Various forms of the following terms: "lung neuroendocrine neoplasms", "LNEN diagnosis", "lung carcinoid", "neuroendocrine tumor therapy" and "LNEN systematic treatment" were used for research. Original articles and meta-analyses were selected after analyzing abstracts. Of publications from the fields of surgical oncology, clinical oncology, and pulmonology, those that comprehensively described the topic were accepted. Finally, 46 articles have been studied for this paper.

Diagnostics

Imaging techniques for LNENs are based on the same principles, as in non-neuroendocrine tumors of this organ.[16] Computed tomography (CT) is fundamental, with magnetic resonance imaging (MRI) further down the line. The undoubted advantage of CT is the rapid acquisition of high-resolution images, along with the ability to visualize 3D lung structures. In the diagnosis of LNENs, it is recommended to use a CT scanner with a 64-row detector. The use of contrast is also an important aspect of the examination. In most cases, as a result of the prominent vascularization of the thoracic area, tumors are demarcated against solid tissue only in the early arterial phase of imaging.[17, 18] It is strongly advisable in hospitals with access to positron emission tomography-computed tomography (PET-CT) to perform this scan as an early treatment control and assessment of metastasis, due to the highest specificity and sensitivity of this type of imaging. Because of the histological differentiation of the tumors in this group and the tumor proliferation rate, appropriate radioactive agents are used. Atypical lesions, and those with a Ki-67 index greater than 10-20% are better visualized after intravenous administration of 18F-fluorodeoxyglucose.[19, 20] One of the crucial biochemical markers is chromogranin A (CgA), a protein secreted from cells of the diffuse endocrine system. Elevated levels of CgA can indicate the presence and growth of a neuroendocrine tumor. Additional markers, such as synaptophysin, neuron-specific enolase (NSE), or other hormonal substances secreted by specific tumors, can also be considered in the LNEN diagnosis.[21] The role of biopsy remains fundamental in confirming the histological nature of the tumor, as well as in determining the grade of malignancy. It is worth emphasizing that a comprehensive diagnosis, including biochemical, imaging, and histopathological examinations, is essential for the effective planning of treatment strategies and prognosis of the disease process.[22] (Table 2) summarizes diagnostic methods for LNENs.

Table 2. Diagnostic methods for LNENs.

Method

Advantages

CT

location and size of LNEN, assessment of metastasis to other areas of the lungs and organs, evaluation of the condition of the lymph nodes

MRI

higher soft tissue resolution than CT, precise analysis of tumor structure, and infiltration of adjacent tissues

PET-CT

use of labeled fluorodeoxyglucose (FDG) to assess tumor metabolic activity, helping to assess the complexity and malignancy of the tumor

Biochemical tests (CgA, synaptophysin, NSE)

evaluating the levels of biochemical markers such as chromogranin A (CgA), synaptophysin, or neuron-specific enolase (NSE)

Histopathological biopsy

crucial for confirming the histological type of the tumor, determination of the grade of malignancy of the tumor, essential for accurate diagnosis

Therapy

LNEN therapy depends on the location of the tumor. In case of resectability, partial or radical resection of the tumor-affected lung is performed, in addition, chemotherapy and perioperative radiotherapy are used if the tumor presents high aggressiveness. In the case of unresectability, therapy depends on the expression of somatostatin receptors on the surface of tumor cells. When somatostatin analog therapy (PRRT) cannot be used, chemotherapeutic agents or immune agents for LNENs are the last line of treatment.

Surgical treatment

The primary method of treatment is a radical surgical procedure. Its purpose is to completely remove the pathological tissue while preserving the functional integrity of the lung as much as possible. Depending on the location and extent of the LNEN, different techniques are used. For centrally localized TCs, conservative resection, i.e. sleeve resection, segmentectomy, or wedge resection is implemented. For patients with ACs, especially in a peripheral location, lobectomy or bilobectomy is often required, and in extreme cases pneumonectomy.[23, 24] For aggressive tumors, preoperative chemotherapy and/or radiation therapy is strongly recommended.[25] In recent years systematic lymphoadenectomy has been increasingly used alongside surgical treatment. If histopathological examination does not find nodes with malignant lesions, then no follow-up lobectomy is required. However, in patients with metastases in these structures, a lobectomy should be performed with adequate pulmonary reserve.[26, 27] Many authors strongly recommend a follow-up chest CT scan, keeping in mind the risk of recurrence after surgical treatment. The recurrence rate after resection is believed to be about 20% in ACs and 5% in TCs. The testing regimen for a typical carcinoma is as follows: CT at 3 and 6 months, then annually for 3 years.[28, 29] At the same intervals, the patient is required to control the concentration of CgA. Longer imaging and laboratory follow-up are required after resection of an atypical lesion. In this case, CT and CgA should be performed 3 months after surgery and then every 6 months for 5 years.[30]

Systemic treatment

Systemic treatment of LNENs is based on the use of somatostatin analogs as first-line agents.[31] In a study by Öberg et al. administration of these drugs to patients resulted in partial remission in 5-10% of cases, arrest of progression in 30-50%, and symptomatic improvement in 40-60%.[32] It is now believed that in SCCs, therapy with somatostatin analogs is not indicated. The five-year survival rate is less than 5%.[33] A study by Caplin et al. showed that median progression-free survival in LNEN patients after lanreotide administration was 32.8 months.[34] A modification and extension of this therapy is peptide receptor radiotherapy (PRRT) and the use of radio-labeled somatostatin analogs. This method is used as the treatment of choice in LNENs with high levels of somatostatin receptor (SSTR) expression. It shows the best response for a subgroup of large-cell neuroendocrine neoplasms. It has used radio-labeled 90Y-octreotide for many years, and 177LuDOTA-Tyr3-octreotate in recent years. Despite its relatively narrow audience, PRRT can be considered a useful option in patients with progressive LCNEC and strong SSTR expression.[35] Ianiello et al. published a study stating that progression-free survival twenty months after 177Lu-Dotatate was 65.2%, compared to only 10.8% in the control group.[36] Traditional chemotherapy is the gold standard for aggressive LNENs with high growth rates and low SSTR expression. There is no single, generally accepted treatment regimen for these lesions. Monotherapy is recommended for patients who undergo chemotherapy as an adjunctive treatment after surgery. Combination therapies, originally intended for patients with inoperable lesions, are more effective.[37, 38] Turner et al. published the results of treating patients with cisplatin, 5-fluorouracil, and streptozotocin. Partial remission was achieved in 25% of patients and inhibition of progression in 51%. The research group of Bajetta et al. evaluated the efficacy of capecitabine and oxaliplatinin a group of 27 patients. The results showed partial remission in 27.5% of patients and inhibition of progression in 35%.[39] The effect of orally administered temozolomide (TMZ) is also noteworthy. On average, it shows a 23% remission response and 40% tumor growth arrest.[40, 41] Nowadays the role of TMZ as monotherapy has been limited. It has been accepted as a substance that helps to stabilize the disease, but no significant remission is achieved. An exception to its use is the exceedingly rare metastasis from the lungs to the brain. TMZ, as a lipophilic substance, shows a good therapeutic effect in this situation.[34] It is worth noting the significant efficacy of combination therapy of TMZ with capecitabine. The paper of Al-Toubah et al. showed as much as 83.2% benefit with this therapy. This percentage includes disease stabilization and remission combined.[42] According to more recent studies, six cycles of cisplatin with etoposide and subsequent irradiation are particularly recommended. In case of resistance to treatment with first-line chemotherapeutics, the patient should be administered topotecan or a combination of cyclophosphamide, epirubicin, and vincristine.[43] In addition, authors currently advocate replacing cisplatin with carboplatin, due to similar efficacy and minor side effects of therapy. Molecular targeted therapy, as the latest weapon in the treatment of LNENs, is based on the use of tyrosine kinase (TK) inhibitors and mTOR inhibitors. Everolimus is a first-line treatment option in cases of advanced, inoperable LNEN, but is also a reasonable option for further lines of therapy.[44, 45] Also, the use of sunitinib is associated with good response rates. Among the 41 patients studied, 43.9% showed remission of the lesion, and 83.4% showed inhibition of progression. The median survival free from recurrence rate was 10.2 months.[46] Other substances in this group, lenvatinib, and surufatinib, are undergoing efficacy trials for the treatment of LNENs.[47] It is also important to mention a new group of drugs that gives promising results in the treatment, immune checkpoint inhibitors. These are antibodies targeting the programmed cell death ligand receptor (PD-L1). They appear to be ineffective as monotherapy, but the combination of pilimumab with nivolumab has shown activity in patients with neuroendocrine tumors, mainly primary lung tumors. Other substances in this group have not shown promise in studies, but they are underway to combine and be administered in therapy.[48, 49] An example of a management algorithm for a LNEN patient is presented in (Figure 1).

 

Figure 1. Management algorithm for patients with LNENs.      (Abbreviations: LNEN – lung neuroendocrine tumor, SR – somatostatin receptor, PRRT – peptide receptor radionuclide therapy, 5-FU – 5-fluorouracil)

Conclusion

LNENs are a rare and heterogeneous group of tumors whose advances in diagnostics and therapy present the dynamic direction of medical research. LNEN diagnosis includes a variety of methods, such as CT and MRI, as well as biochemical tests using markers such as CgA. In clinical practice, the combination of different diagnostic methods is essential to accurately determine the stage of the disease. In the therapeutic area, there is a clear direction for individualized strategies, especially in the context of advances in molecular therapy. Innovative targeted drugs and the development of immunotherapies are emerging as promising options for the treatment of LNENs, especially in cases where traditional approaches are unsuccessful. Radical resection with lymphadenectomy remains an important option in the treatment, but an integrated approach that incorporates modern systemic therapies is increasingly being developed. Over the past decade, there have been exceptional advances in understanding the biology of LNENs and in identifying new therapeutic targets. These findings are pushing toward more effective and personalized forms of treatment, with the prospect of improving therapeutic outcomes and patient quality of life. However, further research and clinical experience are needed to clarify the complex nature of these rare neoplasms and improve diagnostic and therapeutic strategies.

 

Acknowledgments

We would like to express our gratitude to the Editors and the Reviewers for their work in reading and evaluating our paper.

Conflict of interest

None.

Financial support

None.

Ethics statement

None.

References

  1. Mekeres GM, Buhaș CL, Bulzan M, Marian P, Hozan CT. Objective criteria IN evaluating the consequences of the posttraumatic scars. Pharmacophore. 2022;13(1):56-61.
  2. Iancu IA, Hendrick P, Micu DD, Cote A. Pandemic-induced shifts in climate change perception and energy consumption behaviors: A cross-country analysis of Belgium, Italy, Romania, and Sweden. Sustainability. 2023;15(20):14679.
  3. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol. 2017;3(10):1335-42. doi:10.1001/jamaoncol.2017.0589
  4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243-60. doi:10.1097/JTO.0000000000000630
  5. Pantiș C, Cheregi CD, Căiță GA, Szilagyi G. An overview of the distribution and adequacy of human resources working in hospitals. J Organ Behav Res. 2023;8(1):348-55. doi:10.51847/UbjZ8OfNUA
  6. Nam NH, Hung LM, Quynh NT, Dung BV, Ly LD. The impact of trust and opportunistic behavior of employees on business performance: Case study in Vietnam. J Organ Behav Res. 2021;6(1):233-42.
  7. Maralov VG, Sitarov VA, Koryagina II, Kudaka MA, Smirnova OV, Romanyuk LV. The relationship of neuropsychological and personal factors with the attitude to dangers among students. J Organ Behav Res. 2022;7(1):108-24.
  8. Kavitha J, Sivakrishnan S, Srinivasan N. Self medication in today's generation without knowledge as self inflicted harm. Arch Pharm Pract. 2022;13(3):16-22.
  9. Pelosi G, Sonzogni A, Harari S, Albini A, Bresaola E, Marchiò C, et al. Classification of pulmonary neuroendocrine tumors: new insights. Transl Lung Cancer Res. 2017;6(5):513-29. doi:10.21037/tlcr.2017.09.04
  10. Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: Deep sequencing of the four world health organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017;241(4):488-500. doi:10.1002/path.4853
  11. Babalghith AO. Coenzyme Q10 regulates Gene expression of myocardial infarction in the isoproterenol model. Arch Pharm Pract. 2022;13(2):1-6.
  12. Keshavarzian E, Khalifpour Y, Mousavi S, Biranvand N. Coronavirus disease 2019 risk factors in Karun, Iran: A case-control study. Arch Pharm Pract. 2022;13(2):66-8.
  13. Davies RA, Alam NZ, Wright GM. Lung neuroendocrine neoplasms: A single centre surgical series and analysis of staging. ANZ J Surg. 2023;93(6):1543-50. doi:10.1111/ans.18493
  14. Verma P, Pandian SM. Prevalence of endodontically treated posteriors in patients undergoing orthodontic treatment cross-sectional radiographic evaluation. Ann Dent Spec. 2022;10(1):1-6.
  15. Ajwa N, AlRashoud R, AlWehaibi J, AlMazyad A. Orthodontic clear aligner Vs fixed appliances’ influence on oral microbiota and salivary parameters’: A systematic review. Ann Dent Spec. 2021;9(4):16-22.
  16. Savu C, Melinte A, Diaconu C, Stiru O, Gherghiceanu F, Tudorica ȘDO, et al. Lung neuroendocrine tumors: A systematic literature review (Review). Exp Ther Med. 2022;23(2):176. doi:10.3892/etm.2021.11099
  17. Cozzi D, Bicci E, Cavigli E, Danti G, Bettarini S, Tortoli P, et al. Radiomics in pulmonary neuroendocrine tumours (NETs). Radiol Med. 2022;127(6):609-15. doi:10.1007/s11547-022-01494-5
  18. Hörsch D, Schmid KW, Anlauf M, Darwiche K, Denecke T, Baum RP, et al. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): Current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol Res Treat. 2014;37(5):266-76. doi:10.1159/000362430
  19. Bicci E, Cozzi D, Cavigli E, Ruzga R, Bertelli E, Danti G, et al. Reproducibility of CT radiomic features in lung neuroendocrine tumours (NETs) patients: analysis in a heterogeneous population. Radiol Med. 2023;128(2):203-11. doi:10.1007/s11547-023-01592-y
  20. Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, et al. Guidance on 177Lu-DOTATATE peptide receptor radionuclide therapy from the experience of a single nuclear medicine division. J Nucl Med Technol. 2018;46(3):237-44. doi:10.2967/jnmt.118.209148
  21. Iyoda A, Azuma Y, Sano A. Neuroendocrine tumors of the lung: Clinicopathological and molecular features. Surg Today. 2020;50(12):1578-84. doi:10.1007/s00595-020-01988-7
  22. Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N, et al. A comprehensive review on neuroendocrine neoplasms: Presentation, pathophysiology and management. J Clin Med. 2023;12(15):5138. doi:10.3390/jcm12155138
  23. van den Broek MFM, de Laat JM, van Leeuwaarde RS, van de Ven AC, de Herder WW, Dekkers OM, et al. The management of neuroendocrine tumors of the lung in MEN1: Results from the Dutch MEN1 study group. J Clin Endocrinol Metab. 2021;106(2):e1014-27. doi:10.1210/clinem/dgaa800
  24. Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, et al. Recent advances in the management of typical and atypical lung carcinoids. Clin Lung Cancer. 2021;22(3):161-9. doi:10.1016/j.cllc.2020.12.004
  25. Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, et al. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol. 2016;100:167-76. doi:10.1016/j.critrevonc.2016.02.009
  26. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604-20. doi:10.1093/annonc/mdv041
  27. Wolin EM. Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2017;151(5):1141-6. doi:10.1016/j.chest.2016.06.018
  28. Filosso PL, Ferolla P, Guerrera F, Ruffini E, Travis WD, Rossi G, et al. Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis. 2015;7(Suppl 2):S163-71. doi:10.3978/j.issn.2072-1439.2015.04.20
  29. Ramirez RA, Cass AS, Das S, Low SW, Mehrad M, Rickman OB, et al. A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: A narrative review. Transl Lung Cancer Res. 2022;11(12):2567-87. doi:10.21037/tlcr-22-415
  30. He Y, Zhao F, Han Q, Zhou Y, Zhao S. Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors. BMC Cancer. 2021;21(1):141. doi:10.1186/s12885-021-07832-6
  31. Soldath P, Petersen RH. The surgical management of lung neuroendocrine neoplasms. Cancers (Basel). 2023;15(6):1695. doi:10.3390/cancers15061695
  32. Öberg K, Hellman P, Ferolla P, Papotti M; ESMO guidelines working group. neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii120-3. doi:10.1093/annonc/mds267
  33. Myint ZW, McCormick J, Chauhan A, Behrens E, Anthony LB. Management of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: Review and a single center experience. Lung. 2018;196(5):577-81. doi:10.1007/s00408-018-0149-z
  34. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191-9. doi:10.1530/ERC-15-0490
  35. Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced lung carcinoids. Clin Lung Cancer. 2019;20(3):e376-92. doi:10.1016/j.cllc.2019.02.007
  36. Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43(6):1040-6. doi:10.1007/s00259-015-3262-8
  37. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-8.
  38. Al-Toubah T, Grozinsky-Glasberg S, Strosberg J. An update on the management of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). Curr Treat Options Oncol. 2021;22(4):28. doi:10.1007/s11864-021-00828-1
  39. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59(5):637-42. doi:10.1007/s00280-006-0306-6
  40. Barciszewska AM, Gurda D, Głodowicz P, Nowak S, Naskręt-Barciszewska MZ. A new epigenetic mechanism of temozolomide action in glioma cells. PLoS One. 2015;10(8):e0136669. doi:10.1371/journal.pone.0136669
  41. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The pancreas center at Columbia university experience. Cancer Chemother Pharmacol. 2013;71(3):663-70. doi:10.1007/s00280-012-2055-z
  42. Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist. 2020;25(1):e48-52. doi:10.1634/theoncologist.2019-0361
  43. Escobar KM, Vicente-Villardon JL, Villacís Gonzalez RE, Castillo Cordova PH, Sánchez Rodríguez JM, De la Cruz-Velez M, et al. Neuroendocrine tumors: An analysis of prevalence, incidence, and survival in a hospital-based study in Ecuador. Healthcare (Basel). 2022;10(8):1569. doi:10.3390/healthcare10081569
  44. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018;109(1):174-81. doi:10.1111/cas.13427
  45. Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, et al. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish task force group for neuroendocrine tumors (GETNE). Ann Oncol. 2015;26(9):1987-93. doi:10.1093/annonc/mdv252
  46. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep). Ann Oncol. 2019;30:v911.
  47. Capdevila J, Fazio N, López-López C, Teule A, Valle JW, Tafuto S, et al. Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509). J Clin Oncol. 2019;37(4_suppl):332. doi:10.1200/JCO.2019.37.4_suppl.332
  48. D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: A preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4(9):e180077. doi:10.1001/jamaoncol.2018.0077
  49. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39. doi:10.1016/S0140-6736(19)32222-6

 

 

 

 

© Clinical Cancer Investigation Journal
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513